
ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

ΚΩΝΣΤΑΝΤΙΝΟΣ ΔΗΜΑΣ

Αναπληρωτής Καθηγητής

ΕΡΓΑΣΤΗΡΙΟ ΦΑΡΜΑΚΟΛΟΓΙΑΣ, ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ, ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ,
ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ

ΘΕΣΣΑΛΙΑ, Φεβρουάριος 2019

Βιογραφικό Σημείωμα

Όνομα Κωνσταντίνος Δήμας	Θέση Αναπληρωτής Καθηγητής
eRA COMMONS USER NAME	Εργ Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας, Λάρισα Ελλάδα

Πτυχία/Εκπαίδευση			
Εκπαιδευτικά Ιδρύματα	Δίπλωμα	Έτος	Πεδίο
Τμήμα Βιολογίας, Σχολή Θετικών επιστημών, Εθνικό Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα, Ελλάδα	Πτυχίο	1991	Βιολογία
Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Πανεπιστήμιο Ιωαννίνων, Ιωάννινα, Ελλάδα	Διδακτορικό	1999	Φαρμακολογία

A. Ακαδημαϊκές θέσεις/Προϋπηρεσία.

Παρούσα θέση: Αναπληρωτής Καθηγητής, Εργαστήριο Φαρμακολογίας, Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας

Μαρ.-Αυγ 2019: Επισκέπτης Επιστήμονας (Visiting Scientist), Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, USA

Φεβ.-Αύγ. 2014: Επισκέπτης Επιστήμονας (Visiting Scientist, Sabbatical), Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, USA

2011- Μάιος 2013 Λέκτορας, Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας

2003-2011: Ερευνητής Δ', Εργαστήριο Φαρμακολογίας-Φαρμακοτεχνολογίας, Ίδρυμα Ιατροβιολογικών Ερευνών, Ακαδημίας Αθηνών

2007-2011: Επιστημονικός Συνεργάτης, Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας

2001-2002: Μεταδιδακτορικός ερευνητής, Μονάδα Μοριακής Καρκινογένεσης, IARC, Lyon, France

2000-2001: Μεταδιδακτορικός ερευνητής, Τμήμα Κυτταρικής Βιολογίας και Βιοχημείας, Εργαστήριο Νευροανάπτυξης, Ινστιτούτο Παστέρ, Αθήνα

1999-2004: Επιστημονικός Συνεργάτης, International Institute of Anticancer Research-IIAR, Καπανδρίτι, Ελλάδα.

1995-1996: Τμήμα Βιοχημείας, Γ. Παπανικολάου, Κέντρο Πειραματικής Ογκολογίας, Αθήνα,

1994-1999: Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Πανεπιστήμιο Ιωαννίνων, Ιωάννινα, Ελλάδα

1991-1994: Τμήμα Ανοσολογίας/Ιστοσυμβατότητας, Ελληνικό Αντικαρκινικό Ινστιτούτο, Αθήνα.

B. Σεμινάρια

2008, May 19-21, Paris, France. *1st European Course of in Vivo preclinical assays in cancer therapy.*

1992, August 31-September 8 Ionian Village, Greece. *F.E.B.S. Immunology Summer School*

1991, September 9-12, Athens, Greece. *Twenty five Years of Immunoenzymatic techniques*

Γ. Βραβεία/Διακρίσεις

- Βραβείο Καλύτερης Παρουσίασης

E. Sereti, C. Tsimplouli, T. Karagiannelou, A. Tsezou, N. Sakellaridis, **K. Dimas**. *Sigma Receptors [sRs]: Study of their role in cancer and the development of new targeted anticancer therapies*. Abstract book: page 37 (P22). 2016, 1st Training School, COST ACTION CM1407, Belgrade, Serbia.

- Βραβείο Καλύτερης Προφορικής Παρουσίασης
B. Cevatemre, M. Erkisa, N. Aztopal, Didem Karakaş, P. Alper, C. Tsimplouli, E. Sereti, **K. Dimas**, E. I. Ikitimur Armutak, E. Gurel Gurevin, A. Uvez, M. Mori, S. Berardozzi, C. Ingallina, B. Botta, E. Ulukaya. *The Plant-Derived Triterpenoid Pristimerin is a Potent Anticancer Agent Due to Its Cytotoxic Activity on Breast Cancer in vitro and in vivo*. Abstract book: Page 50 (S-005). 2016, 6th Multidisciplinary Cancer Research Congress, Konya, Turkey.
- 2001-2003: WHO Μεταδιδακτορικός υπότροφος (STA), Μονάδα Μοριακής Καρκινογένεσης, IARC, Lyon, France

E. Πρωτότυπα επιστημονικά άρθρα σε διεθνή περιοδικά με κριτές (με χρονολογική σειρά).

- [1] Vasileiou C, Befani C, **Dimas K**, Liakos P, Papandreou C. FGF-2 and HGF reverse abiraterone's effect on intracellular levels of DHT in androgen dependent and androgen independent prostate cancer cell lines. *JBUON*, 2019 *in press*
- [2] Magouliotis DE, Tasiopoulou VS, **Dimas K**, Sakellaridis N, Svokos KA, Svokos AA, Zacharoulis D Transcriptomic analysis of the Aquaporin (AQP) gene family interactome identifies a molecular panel of four prognostic markers in patients with pancreatic ductal adenocarcinoma. *Pancreatology*. 2019 Apr;19(3):436-442. doi: 10.1016/j.pan.2019.02.006. Epub 2019 Feb 11
- [3] Kamposioras K, Tsimplouli C, Verbeke C, Anthoney A, Daoukopoulou A, Papandreou CN, Sakellaridis N, Vassilopoulos G, Potamianos SP, Liakouli V, Migneco G, Del Galdo F, **Dimas K**. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. *Int J Oncol*. 2019 Feb;54(2):537-549. doi: 10.3892/ijo.2018.4640. Epub 2018 Nov 21.
- [4] Bilalis P, Skoulas D, Karatzas A, Marakis J, Stamogiannos A, Tsimblouli C, Sereti E, Stratikos E, **Dimas K**, Vlassopoulos D, Iatrou H. Self-Healing pH- and Enzyme Stimuli-Responsive Hydrogels for Targeted Delivery of Gemcitabine To Treat Pancreatic Cancer. *Biomacromolecules*. 2018 Sep 10;19(9):3840-3852. doi: 10.1021/acs.biomac.8b00959. Epub 2018 Aug 27.
- [5] Yiallouris A, Patrikios I, Johnson EO, Sereti E, **Dimas K**, De Ford C, Fedosova NU, Graier WF, Sokratous K, Kyriakou K, Stephanou A. Annonacin promotes selective cancer cell death via NKA-dependent and SERCA-dependent pathways. *Cell Death Dis*. 2018 Jul 9;9(7):764. doi: 10.1038/s41419-018-0772-x.
- [6] Gurel-Gurevin E, Kiyani HT, Esener OBB, Aydinlik S, Uvez A, Ulukaya E, **Dimas K**, Armutak EI. Chloroquine Used in Combination with Chemotherapy Synergistically Suppresses Growth and Angiogenesis In Vitro and In Vivo. *Anticancer Res*. 2018 Jul;38(7):4011-4020
- [7] Milošević Z, Banković J, Dinić J, Tsimplouli C, Sereti E, Dragoj M, Paunović V, Milovanović Z, Stepanović M, Tanić N, **Dimas K**, Pešić M. Potential of the dual mTOR kinase inhibitor AZD2014

- to overcome paclitaxel resistance in anaplastic thyroid carcinoma. *Cell Oncol (Dordr)*. 2018 Aug;41(4):409-426. doi: 10.1007/s13402-018-0380-x. Epub 2018 May 22.
- [8] Cevatemre B, Erkisa M, Aztopal N, Karakas D, Alper P, Tsimplouli C, Sereti E, **Dimas K**, Armutak EII, Gurevin EG, Uvez A, Mori M, Berardozzi S, Ingallina C, D'Acquarica I, Botta B, Ozpolat B, Ulukaya E. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autophagy in breast cancer. *Pharmacol Res*. 2017 Dec 1. pii: S1043-6618(17)30993-3.
- [9] Dragoj M, Bankovic J, Sereti E, Stojanov SJ, **Dimas K**, Pesic M, Stankovic T. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors. *Invest New Drugs*. 2017 Jul 22. doi: 10.1007/s10637-017-0494-4. [Epub ahead of print]
- [10] Stagno MJ, Zacharopoulou N, Bochem J, Tsapara A, Pelzl L, Al-Maghout T, Kallergi G, Alkahtani S, Alevizopoulos K, **Dimas K**, Calogeropoulou T, Warmann SW, Lang F, Schmid E, Stournaras C. Istaroxime Inhibits Motility and Down-Regulates Orail Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells. *Cell Physiol Biochem*. 2017;42(4):1366-1376. doi: 10.1159/000479200. Epub 2017 Jul 14.
- [11] Tsangaris GT, **Dimas K**, Malamou A, Katsafadou A, Papathanasiou C, Stravopodis DJ, Vorgias CE, Gazouli M, Anagnostopoulos AK. Molecular Proteomic Characterization of a Pediatric Medulloblastoma Xenograft. *Cancer Genomics Proteomics*. 2017 Jul-Aug;14(4):267-275.
- [12] Yoon S, Huang KW, Reebye V, Spalding D, Przytycka TM, Wang Y, Swiderski P, Li L, Armstrong B, Reccia I, Zacharoulis D, **Dimas K**, Kusano T, Shively J, Habib N, Rossi JJ. Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. *Mol Ther Nucleic Acids*. 2017 Mar 17; 6: 80-88. doi: 10.1016/j.omtn.2016.
- [13] Ikitimur-Armutak EI, Gurel-Gurevin E, Kiyan HT, Aydinlik S, Yilmaz VT, **Dimas K**, Ulukaya E. Anti-angiogenic effect of a Palladium(II)-Saccharinate Complex of Terpyridine in vitro and in vivo. *Microvasc Res*. 2017 Jan;109: 26-33
- [14] Vaiou M, Pangou E, Liakos P, Sakellaridis N, Vassilopoulos G, **Dimas K**, Papandreou C. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity. *J Cancer Res Clin Oncol*. 2016 Oct;142 (10):2141-58
- [15] Alevizopoulos K, **Dimas K**, Papadopoulou N, Schmidt EM, Tsapara A, Alkahtani S, Honisch S, Prousis KC, Alarifi S, Calogeropoulou T, Lang F, Stournaras C. Functional characterization and anti-cancer action of the clinical phase II cardiac Na⁺/K⁺ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor. *Oncotarget*. 2016 Mar 24. doi: 10.18632/oncotarget.8329.
- [16] **Dimas K**, Tsimplouli C, Houchen C, Pantazis P, Sakellaridis N, Tsangaris GT, Anastasiadou E, Ramanujam RP. An Ethanol Extract of Hawaiian Turmeric: Extensive In Vitro Anticancer Activity Against Human Colon Cancer Cells. *Altern Ther Health Med*. 2015; 21 Suppl 2:46-54.
- [17] Anagnostopoulos AK, Papathanasiou C, Karamolegou K, Anastasiadou E, **Dimas KS**, Kontos H, Koutsopoulos A, Prodromou N, Tzortzatos-Stathopoulou F, Tsangaris GT. Proteomic Studies of Pediatric Medulloblastoma Tumors with 17p Deletion. *J Proteome Res*. 2015 Jan 26
- [18] Moraitis D, Karanikou M, Liakou C, **Dimas K**, Tzimas G, Tseleni-Balafouta S, Patsouris E, Rassidakis GZ, Kouvaraki MA. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas. *Surgery*. 2014 Dec; 156(6):1542-9.

- [19] Honisch S, Alkahtani S, Kounenidakis M, Liu G, Alarifi S, Al-Yahya H, **Dimas K**, Al Kahtane AA, Prousis KC, Al-Dahmash B, Calogeropoulou T, Alevizopoulos K, Lang F, Stournaras C. A steroidal Na⁺/K⁺ ATPase Inhibitor Triggers Pro-Apoptotic Signaling and Induces Apoptosis in Prostate and Lung Tumor Cells. *Anticancer Agents Med Chem.* 2014; 14(8):1161-8.
- [20] Iatrou H, **Dimas K**, Gkikas M, Tsimblouli C, Sofianopoulou S. Polymersomes from Polypeptide Containing Triblock Co- and Terpolymers for Drug Delivery against Pancreatic Cancer: Asymmetry of the External Hydrophilic Blocks. *Macromol Biosci.* 2014 May 19. doi: 10.1002/mabi.201400137. [Epub ahead of print].
- [21] Ulukaya E, Sarimahmut M, Cevatemre B, Ari F, Yerlikaya A, **Dimas K**. Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro. *Biomed Pharmacother.* 2014 May;68(4):477-82.
- [22] Drago L, Boot W, **Dimas K**, Malizos K, Hänsch GM, Stuyck J, Gawlitta D, Romanò CL. Does Implant Coating With Antibacterial-Loaded Hydrogel Reduce Bacterial Colonization and Biofilm Formation in Vitro? *Clin Orthop Relat Res.* 2014 Nov; 472(11):3311-23.
- [23] **Dimas K**, Papadopoulou N, Baskakis C, Prousis KC, Tsakos M, Alkahtani S, Honisch S, Lang F, Calogeropoulou T, Alevizopoulos K, Stournaras C. Steroidal Cardiac Na⁺/K⁺ ATPase Inhibitors Exhibit Strong Anti-Cancer Potential in Vitro and in Prostate and Lung Cancer Xenografts in Vivo. *Anticancer Agents Med Chem.* 2014 Jun; 14(5):762-70.
- [24] Thalassitis A, Katsori AM, **Dimas K**, Hadjipavlou-Litina DJ, Pylaris F, Sakellaridis N, Litinas KE Synthesis and biological evaluation of modified purine homo-N-nucleosides containing pyrazole or 2-pyrazoline moiety. *J Enzyme Inhib Med Chem.* 2014 Feb; 29(1):109-17.
- [25] Riganas S, Papanastasiou I, Foscolos GB, Tsoinis A, Serin G, Mirjolet JF, **Dimas K**, Kourafalos VN, Eleutheriades A, Moutsos VI, Khan H, Georgakopoulou S, Zaniou A, Prassa M, Theodoropoulou M, Mantelas A, Pondiki S, Vamvakides A. New adamantane phenylalkylamines with sigma-receptors binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain. *J Med Chem.* 2012 Nov 26; 55(22):10241-61.
- [26] Tsirmoula S, **Dimas K**, Hatziapostolou M, Lamprou M, Ravazoula P, Papadimitriou, E. Implication of pleiotrophin in human PC3 prostate cancer cell growth *in vivo*. *Cancer Sci.* 2012 Oct;103(10):1826-32
- [27] Almeida C, Hemberger Y, Schmitt SM, Bouhired S, Natesan L, Kehraus S, **Dimas K**, Gütschow M, Bringmann G, König GM. Marilines A-C: Novel Phthalimidines from the Sponge-Derived Fungus *Stachylidium* sp. *Chemistry.* 2012 Jul 9;18(28):8827-34
- [28] Riganas S, Papanastasiou I, Foscolos GB, Tsoinis A, **Dimas K**, Kourafalos VN, Eleutheriades A, Moutsos VI, Khan H, Margarita P, Georgakopoulou S, Zaniou A, Theodoropoulou M, Mantelas A, Pondiki S, Vamvakides A. New Adamantane Derivatives with Sigma Affinity and Antiproliferative Activity. *Med Chem.* 2012 Jul;8(4):569-86
- [29] Riganas S, Papanastasiou I, Foscolos GB, Tsoinis A, Bourguignon JJ, Serin G, Mirjolet JF, **Dimas K**, Kourafalos VN, Eleutheriades A, Moutsos VI, Khan H, Georgakopoulou S, Zaniou A, Prassa M, Theodoropoulou M, Pondiki S, Vamvakides A. Synthesis, σ_1 , σ_2 -receptors binding affinity and antiproliferative action of new C1-substituted adamantanes. *Bioorg Med Chem.* 2012 May 15;20(10):3323-31
- [30] Thanasopoulou A, Stravopodis DJ, **Dimas KS**, Schwaller J, Anastasiadou E. Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control. *PLoS One.* 2012;7(2):e31007
- [31] Kouvaraki MA, Liakou C, Paraschi A, **Dimas K**, Patsouris E, Tseleni-Balafouta S, Rassidakis GZ, Moraitis D. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. *Surgery.* 2011 Dec;150(6):1258-65

- [32] Kontogiannopoulos KN, Assimopoulou AN, **Dimas K**, Papageorgiou VP. Shikonin-loaded liposomes as a new drug delivery system: physicochemical characterization and *in vitro* cytotoxicity. *Eur. J. Lipid Sci. Technol.* 2011, 113, 1113–1123
- [33] Ulukaya E, Ari F, **Dimas K**, Ikitimur EI, Guney E, Yilmaz VT. Anti-cancer activity of a novel palladium (II) complex on human breast cancer cells *in vitro* and *in vivo*. *Eur J Med Chem.* 2011 Oct; 46(10):4957-63.
- [34] Mahaira LG, Tsimplouli C Sakellaridis N, Alevizopoulos K, Demetzos C, Han Z, Pantazis P, **Dimas K**. The labdane diterpene sclareol (labd-14-ene-8, 13-diol) induces apoptosis in human 3 tumor cell lines and suppression of tumor growth *in vivo* via a p53-independent mechanism of action. *Eur J Pharmacol.* 2011 Sep;666(1-3):173-82
- [35] Ulukaya E, Ari F, **Dimas K**, Sarimahmut M, Guney E, Sakellaridis N, Yilmaz VT. Cell death-inducing effect of novel palladium (II) and platinum (II) complexes on non-small cell lung cancer cells *in vitro*. *J Cancer Res Clin Oncol.* 2011 Oct; 137(10):1425-34.
- [36] Tsimplouli C, Demetzos C, Hadzopoulou-Cladaras M, Pantazis P, **Dimas K**. *In vitro* activity of dietary flavonol congeners against human cancer cell lines. *Eur J Nutr.* 2011 May 20.
- [37] Gardikis K, Fessas D, Signorelli M, **Dimas K**, Tsimplouli C, Ionov M, Demetzos C. A new chimeric advanced Drug Delivery nano System (chi-aDDnS) composed of PAMAM G 3.5 dendrimer and liposomes as Doxorubicin's carrier. *In vitro* pharmacological studies. *Journal of Nanoscience and Nanotechnology* 2011, May; 11(5):3764-72.
- [38] Katsori AM, **Dimas K**, Chatzopoulou M, Kontogiorgis C, Patsilinakos A, Trangas T, Hadjipavlou-Litina D Curcumin analogues as possible anti-proliferative & anti-inflammatory agents. *Eur J Med Chem.* 2011 Jul;46(7): 2722-35
- [39] Anagnostopoulos AK, **Dimas KS**, Papatthanassiou C, Braoudaki M, Anastasiadou E, Vougas K, Karamolegou K, Kontos H, Prodromou N, Tzortzatou-Stathopoulou F, Tsangaris GT. Proteomics studies of childhood pilocytic astrocytoma. *J Proteome Res.* 2011 May 6; 10(5):2555-65.
- [40] Pandelidou M, **Dimas K**, Georgopoulos A, Hatziantoniou and Demetzos C. Preparation and Characterization of Lyophilised EGG PC Liposomes incorporating Curcumin and Evaluation of its Activity against Colorectal Cancer Cell Lines. *J Nanosci Nanotechnol.* 2011 Feb; 11(2):1259-66.
- [41] Gardikis K, Tsimplouli C, **Dimas K**, Micha-Screttas M, Demetzos C. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers. *Int J Pharm.* 2010 Dec 15; 402(1-2):231-7.
- [42] Gardikis K, **Dimas K**, Georgopoulos A, Kaditi E, Pispas S and Demetzos C. β -lactam functionalized poly (isoprene-b-ethylene oxide) amphiphilic block copolymer micelles as a new nanocarrier system for curcumin. *Current Nanoscience*, 2010 Jun; 6(3): 277-284.
- [43] Saroglou V, Karioti A, Rancic A, **Dimas K**, Koukoulitsa C, Zervou M, Skaltsa H. Sesquiterpene lactones from *Anthemis melanolepis* and their antibacterial and cytotoxic activities. Prediction of their pharmacokinetic profile. *J Nat Prod.* 2010 Feb 26;73(2):242-6
- [44] Gu S, Papadopoulou N, Gehring EM, Nasir O, **Dimas K**, Bhavsar SK, Föllner M, Alevizopoulos K, Lang F, Stournaras C. Functional membrane androgen receptors in colon tumors trigger proapoptotic responses *in vitro* and reduce drastically tumor incidence *in vivo*. *Mol Cancer.* 2009 Dec; 1;8:114
- [45] Han Z, **Dimas K**, Tian X, Wang Y, Hemmi H, Yamada K, Kato N, Pantazis P, Ramanujam RJ, Anant S, Wyche JH, Houchen CW. 14-3-3 sigma-dependent resistance to cisplatin. *Anticancer Res.* 2009 Jun;29(6):2009-14.
- [46] **Dimas K**, Hatziantoniou S, Wyche JH, Pantazis P. A mastic gum extract induces suppression of growth of human colorectal tumor xenografts in immunodeficient mice. *In Vivo.* 2009 Jan-Feb; 23(1):63-8.

- [47] Lagadinou ED, Ziros P, Tsopra O, **Dimas K**, Thanopoulou E, Kouraklis-Symeonidis A, Karakantza M, Pantazis P, Zoumbos NC. Absence of JNK activation is a predictor of anthracycline resistance in AML. *Leukemia* 2008 Oct;22(10):1899-908.
- [48] **Dimas K**, Tsimplouli C, Anagnostopoulos A, Mahaira L, Iliopoulou E, Perez S, Vougas K and Tsangaris GT. The Proteome Profile of Two Cell Lines and their Xenografts Isolated from a Patient with Clear Cell Sarcoma (Soft Tissue Melanoma). *Cancer Genomics & Proteomics* 2008, 5: 175-238
- [49] **Dimas K**, Hatziantoniou S, Tseleni S, Khan H, Georgopoulos A, Alevizopoulos K, Wyche JH, Pantazis P, Demetzos C. Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. *Apoptosis*. 2007 Apr; 12(4):685-94.
- [50] Balan KV, Prince J, Han Z, **Dimas K**, Cladaras M, Wyche JH, Sitaras NM, Pantazis P. Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from *Pistacia lentiscus* L. var. *chia*. *Phytomedicine*. 2007 Apr; 14(4):263-72.
- [51] Tamvakopoulos C, **Dimas K**, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, Wyche JH, Pantazis P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. *Clin Cancer Res*. 2007 Feb 15; 13(4):1269-77.
- [52] Paradissis A, Hatziantoniou S, Georgopoulos A, Psarra AM, **Dimas K**, Demetzos C. Liposomes modify the subcellular distribution of sclareol uptake by HCT-116 cancer cell lines. *Biomed Pharmacother*. 2007 Feb-Apr; 61(2-3):120-4.
- [53] Matsingou C, **Dimas K**, Demetzos C. Design and development of liposomes incorporating a bioactive labdane-type diterpene. In vitro growth inhibiting and cytotoxic activity against human cancer cell lines. *Biomed Pharmacother*. 2006 May; 60(4):191-9.
- [54] **Dimas K**, Papadaki M, Tsimplouli C, Hatziantoniou S, Alevizopoulos K, Pantazis P, Demetzos C. Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs. *Biomed Pharmacother*. 2006 Apr; 60(3):127-33.
- [55] Papagiannaros A, Hatziantoniou S, **Dimas K**, Papaioannou GT, Demetzos C. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. *Biomed Pharmacother*. 2006 Jan; 60(1):36-42.
- [56] Balan KV, Sitaras NM, **Dimas K**, Han Z, Wyche JH, Pantazis P. Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell line. *Chemotherapy*. 2006; 52(3):137-46.
- [57] Saroglou V, Karioti A, Demetzos C, **Dimas K**, Skaltsa H. Sesquiterpene lactones from *Centaurea spinosa* and their antibacterial and cytotoxic activities. *J Nat Prod*. 2005 Sep; 68(9):1404-7.
- [58] Papagiannaros A, Hatziantoniou S, Lelong-Rebel IH, Papaioannou GT, **Dimas K**, Demetzos C. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice. *In Vivo*. 2006 Jan-Feb; 20(1):129-35.
- [59] Hatziantoniou S, **Dimas K**, Georgopoulos A, Sotiriadou N, Demetzos C. Cytotoxic and antitumor activity of liposome-incorporated sclareol against cancer cell lines and human colon cancer xenografts. *Pharmacol Res*. 2006 Jan; 53(1):80-7.
- [60] Matsingou C, Hatziantoniou S, Georgopoulos A, **Dimas K**, Terzis A, Demetzos C. Labdane-type diterpenes: thermal effects on phospholipid bilayers, incorporation into liposomes and biological activity. *Chem Phys Lipids*. 2005 Dec; 138(1-2):1-11.

- [61] Papagiannaros A, **Dimas K**, Papaioannou GT, Demetzos C. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. *Int J Pharm.* 2005 Sep 30; 302(1-2):29-38.
- [62] Balan KV, Demetzos C, Prince J, **Dimas K**, Cladaras M, Han Z, Wyche JH, Pantazis P. Induction of apoptosis in human colon cancer HCT116 cells treated with an extract of the plant product, Chios mastic gum. *In Vivo.* 2005 Jan-Feb; 19(1):93-102.
- [63] Malisiova F, Hatziantoniou S, Kletsas D, **Dimas K**, Demetzos C. Liposomal formulations from phospholipids of Greek almond oil. Properties and biological activity. *Z. Naturforsch, Bioscience* 2004, 59:330-334
- [64] Goniotaki M, Hatziantoniou S, **Dimas K**, Wagner M, Demetzos C. Encapsulation of naturally occurring flavonoids into liposomes: physicochemical properties and biological activity against human cancer cell lines. *J Pharm Pharmacol.* 2004 Oct; 56(10):1217-24.
- [65] Pluquet O, North S, Bhoomik A, **Dimas K**, Ronai Z, Hainaut P. The cytoprotective aminothioliol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. *J Biol Chem.* 2003 Apr 4; 278(14):11879-87.
- [66] Koukoulitsa E, Skaltsa H, Karioti A, Demetzos C, **Dimas K**. Bioactive sesquiterpene lactones from *Centaurea* species and their cytotoxic/cytostatic activity against human cell lines in vitro. *Planta Med.* 2002 Jul; 68(7):649-52.
- [67] Kolocouris A, **Dimas K**, Pannecouque C, Witvrouw M, Foscolos GB, Stamatiou G, Fytas G, Zoidis G, Kolocouris N, Andrei G, Snoeck R, De Clercq E. New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazone: cell growth inhibitory, antiviral and antimicrobial activity evaluation. *Bioorg Med Chem Lett.* 2002 Mar 11; 12(5):723-7.
- [68] Maswadeh H, Demetzos C, **Dimas K**, Loukas YL, Georgopoulos A, Mavromoustakos T, Papaioannou GT. In-vitro cytotoxic/cytostatic activity of anionic liposomes containing vinblastine against leukaemic human cell lines. *J Pharm Pharmacol.* 2002 Feb; 54(2):189-96.
- [69] Demetzos C, **Dimas K**, Hatziantoniou S, Anastasaki T, Angelopoulou D. Cytotoxic and anti-inflammatory activity of labdane and cis-clerodane type diterpenes. *Planta Med.* 2001 Oct; 67(7):614-8.
- [70] Maswadeh H, Demetzos C, **Dimas K**, Hatziantoniou S, Georgopoulos A, Rallis M, Dallas P, Papaioannou G. Accumulation of vinblastine into transfersomes and liposomes in response to a transmembrane ammonium sulfate gradient and their cytotoxic/cytostatic activity in vitro. *Anticancer Res.* 2001 Jul-Aug; 21(4A):2577-83.
- [71] **Dimas K**, Demetzos C, Vaos V, Ioannidis P, Trangas T. Labdane type diterpenes down-regulate the expression of c-Myc protein, but not of Bcl-2, in human leukemia T-cells undergoing apoptosis. *Leuk Res.* 2001 Jun; 25(6):449-54.
- [72] Angelopoulou D, Demetzos C, **Dimas C**, Perdetzoglou D, Loukis A. Essential oils and hexane extracts from leaves and fruits of *Cistus monspeliensis*. Cytotoxic activity of ent-13-epi-manoyl oxide and its isomers. *Planta Med.* 2001 Mar; 67(2):168-71.
- [73] Maswadeh H, Hatziantoniou S, Demetzos C, **Dimas K**, Georgopoulos A, Rallis M. Encapsulation of vinblastine into new liposome formulations prepared from triticum (wheat germ) lipids and its activity against human leukemic cell lines. *Anticancer Res.* 2000 Nov-Dec; 20(6B):4385-90.
- [74] **Dimas K**, Demetzos C, Angelopoulou D, Kolokouris A, Mavromoustakos T. Biological activity of myricetin and its derivatives against human leukemic cell lines in vitro. *Pharmacol Res.* 2000 Nov; 42(5):475-8.

- [75] **Dimas K**, Demetzos C, Mitaku S, Marselos M, Tzavaras T, Kokkinopoulos D. Cytotoxic activity of kaempferol glycosides against human leukaemic cell lines in vitro. *Pharmacol Res.* 2000 Jan; 41(1):83-86.
- [76] **Dimas K**, Demetzos C, Vaos B, Marselos M, Kokkinopoulos D. Cytotoxic and antiproliferative effects of heptaacetyltiliroside on human leukemic cell lines. *Leuk Res.* 1999 Nov; 23(11):1021-33.
- [77] **Dimas K**, Demetzos C, Mitaku S, Vaos B, Marselos M, Tzavaras T, Kokkinopoulos D. Cytotoxic activity and antiproliferative effects of a new semi-synthetic derivative of Ent-3 beta-hydroxy-13-epi-manoyl oxide on human leukemic cell lines. *Anticancer Res.* 1999 Sep-Oct; 19(5B):4065-72.
- [78] Mitrocotsa D, Bosch S, Mitaku S, **Dimas C**, Skaltsounis AL, Harvala C, Briand G, Roussakis C. Cytotoxicity against human leukemic cell lines, and the activity on the expression of resistance genes of flavonoids from *Platanus orientalis*. *Anticancer Res.* 1999 May-Jun; 19(3A):2085-8.
- [79] **Dimas K**, Kokkinopoulos D, Demetzos C, Vaos B, Marselos M, Malamas M, Tzavaras T. The effect of sclareol on growth and cell cycle progression of human leukemic cell lines. *Leuk Res.* 1999 Mar; 23(3):217-34.
- [80] **Dimas K**, Demetzos C, Marsellos M, Sotiriadou R, Malamas M, Kokkinopoulos D. Cytotoxic activity of labdane type diterpenes against human leukemic cell lines in vitro. *Planta Med.* 1998 Apr; 64(3):208-11.
- [81] Demetzos C, Magiatis P, Typas MA, **Dimas K**, Sotiriadou R, Perez S, Kokkinopoulos D. Biotransformation of the flavonoid tiliroside to 7-methylether tiliroside: bioactivity of this metabolite and of its acetylated derivative. *Cell Mol Life Sci.* 1997 Jul; 53(7):587-92.
- [82] Sotiriadou R, Kokkinopoulos D, Stinios J, **Dimas C**, Trangas T, Perez S. delta IK17: an antigen expressed on human lymphocytes. *Int J Biol Markers.* 1996 Oct-Dec; 11(4):183-9.

Στ. Άρθρα επισκόπησης (Reviews)

- [1] Liarou E., Varlas S, Skoulas D, Tsimblouli C, Sereti E, **Dimas K**, Iatrou, H. Smart polymersomes and hydrogels from polypeptide-based polymer systems through α -amino acid N-carboxyanhydride ring-opening polymerization. From chemistry to biomedical applications. *Progress in Polymer Science.* Volume 83, August 2018, Pages 28-78 (Κατόπιν πρόσκλησης)
- [2] Gerogianni K, Tsezou A, **Dimas K**. Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. *Mol Diagn Ther.* 2018 Jun;22(3):297-314. doi: 10.1007/s40291-018-0330-3.
- [3] Sereti E, Karagianellou T, Kotsoni I, Magouliotis D, 2, Kamposioras K, Sakellaridis N, Zacharoulis D, **Dimas K**. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging precious allies in the war on a devastating cancer? *J Proteomics.* 2018 Sep 30;188:107-118. doi: 10.1016/j.jprot.2018.01.012. Epub 2018 Feb 14 (Κατόπιν πρόσκλησης)
- [4] Papadopoulos V, Tsapakidis K, Riobo Del Galdo NA, Papandreou CN, Del Galdo F, Anthony A, Sakellaridis N, **Dimas K**, Kamposioras K. The Prognostic Significance of the Hedgehog Signaling Pathway in Colorectal Cancer. *Clin Colorectal Cancer.* 2016 Jun;15(2):116-27
- [5] **Dimas KS**, Pantazis P, Ramanujam R. Chios Mastic Gum: A Plant-produced Resin Exhibiting Numerous Diverse Pharmaceutical and Biomedical Properties. *In Vivo.* 2012 Sep;26(5):777-85

Z. Κεφάλαια σε βιβλία (κατόπιν πρόσκλησης)

- 1) **Dimas K., Sereti E and Sakellaridis N. (2018) Kaposi's Sarcoma.** Reference Module in Biomedical Sciences. Elsevier 2018 <https://doi.org/10.1016/B978-0-12-801238-3.05106-0>
- 2) **Dimas K.,** Ulukaya E. and Sakellaridis N. (2015) Salivary Gland Tumors. Reference Module in Biomedical Sciences. Elsevier. 12-Jun-15 doi: 10.1016/B978-0-12-801238-3.99478-9.
- 3) **Dimas K.** and Sakellaridis N. (2015) Choriocarcinoma. Reference Module in Biomedical Sciences. Elsevier. 12-Jun-15 doi: 10.1016/B978-0-12-801238-3.99474-1.
- 4) **Dimas K.** and Sakellaridis N. (2015) Kaposi's Sarcoma. Reference Module in Biomedical Sciences. Elsevier. 9-Apr-15 doi: 10.1016/B978-0-12-801238-3.05106-0.
- 5) **Dimas K.,** Ulukaya E. and Sakellaridis N. (2015) Cancer of the Eye (Intraocular Cancer). Reference Module in Biomedical Sciences. Elsevier. 12-Jun-15 doi: 10.1016/B978-0-12-801238-3.99473-X.
- 6) Gardikis K, Mourelatou EA, Ionov M, Aserin A, Libster D, Klajnert B, Bryszewska M, Garti N, Majoral JP, **Dimas K** and Demetzos C. Natural and Synthetic Biomaterials as Composites of Advanced Drug Delivery Nano Systems (ADDNSS). Biomedical Applications. Barbara Klajnert, Ling Peng, Valentin Cena (Eds), Dendrimers in Biomedical Applications 2013, Royal Society of Chemistry.
- 7) **Dimas K,** Tsimplouli C, Ramanujam R, Pantazis P, Sakellaridis N'A Tour to the Stars of the Immunodeficient Mice-Galaxy , Leon V. Berhardt (Ed), Advances in Medicine and Biology. Volume 57, Nova Science Publishers, NY, USA 2012
- 8) Tsimplouli C, Pantazis P, Alevizopoulos K, Ulukaya E, **Dimas K.** Patient-Derived Xenografts: Real-Time Modeling of Cancer, Leon V. Berhardt (Ed), Advances in Medicine and Biology, Volume 57, Nova Science Publishers, NY, USA, 2012
- 9) Leondaritis G, Koliou X, Johnson S, Li C, Florakis A, **Dimas K,** Sakellaridis N and Mangoura D. Interplay Between Protein Kinase C Isoforms Alpha and Epsilon, Neurofibromin, and the Ras/MAPK Pathway in Neuroblastoma Differentiation. Neuroblastoma - Present and Future, Hiroyuki Shimada (Ed.), InTech, NY, USA, 2012
- 10) Pantazis P, **Dimas K,** Wyche JH, AnantS, Houchen CW, Panyam J, and Ramanujam RP. Preparation of siRNA-Encapsulated PLGA Nanoparticles for Sustained Release of siRNA and Evaluation of Encapsulation Efficiency. Mikhail Soloviev (ed.), Nanoparticles in Biology and Medicine: Methods and Protocols, Methods in Molecular Biology, vol. 906, Springer Science+Business Media, LLC 2012.
- 11) Paradissis A, Hatziantoniou S, Georgopoulos A, **Dimas K,** and Demetzos C. Uptake Studies of Free and Liposomal Sclareol by MCF-7 and H-460 Human Cancer Cell Lines. Nanomaterials and Nanosystems for Biomedical Applications; Editor M. Reza Mozafari, Massey University, New Zealand, 2007, Springer, the Netherlands.
- 12) Demetzos C, **Dimas K.** Labdane type diterpenes: chemistry and biological activity. *Series of Books 'Studies in Natural Product Chemistry'*; Editor Atta-ur- Rahman, University of Karachi, Karachi, Pakistan vol. 25, 2001 ELSEVIER Ltd.

H. Διπλώματα Ευρεσιτεχνίας

- 1) **GR No 1009114,** Linear Pentablock Polypeptidic and Hybrid Polymers to give In Situ Forming Self-Healing pH and Temperature Responsive Hydrogels for Localized Targeted Delivery of Gemcitabine.
- 2) **TR 201406644B** A palladium complex with high anticancer activity.

Σε εθνικές φάσεις:

JP 2017-520525 A 2017.7.27

WO 2015/17095A1

USP application US2017/0106000A1, April 20, 2017

3) **GR No 1003509**, Labdane diterpenes in liposomal form; *in vitro* studies in human leukaemia cell lines of the new liposomal products.

4) **US Patent 6652877B1** “Pharmaceutical Formulations Comprising Labdane for the Treatment of Tumors or Leukemias”.

Επίσης

CA 2390553

AU 773462

WO 01/34116

5) **PCT application (No 990100387/8.11.2000/IPN: WO 01/34116A)**, “Liposomes composition containing at least one a) labd-13-ene-8a, 15-diol and/or derivatives b) labd-14-ene-8, 13-diol c) 3β-hydroxy-labd-14-ene-8, 13-epoxy and/or derivatives, or a plant extract containing them; pharmaceutical formulation for the treatment of tumors or leukemias”.

6) **GR No 1004988**, Liposomal formulation comprising phospholipids, lipids and a labdane-type diterpene.

Θ. Κριτής εργασιών σε διεθνή επιστημονικά περιοδικά (κατόπιν πρόσκλησης)

• Editorial Boards

-International Journal of Chronic Diseases, Hindawi Publishing Corporation (<http://www.hindawi.com/journals/ijcd/editors/>)

-American Journal of Cancer Therapy and Pharmacology, Ivy Union Publishing LLC, USA
Senior Editorial Board (<http://ivyunion.org/index.php/ajctp/about/editorialTeam>)

-Medicine, open access journal, (<http://journals.lww.com/md-journal/Pages/Open-Access-Editorial-Board.aspx#d>)

-Medicina, MDPI (<https://www.mdpi.com/journal/medicina/editors>)

• Peer Reviews for

Analytical Chemistry Insights, *Advances in Pharmacology*, *Apoptosis*, *Biochemical Pharmacology* (*Outstanding and Recognized reviewer, September 2015*), *Cancer Research*, *Carcinogenesis*, *International Journal of Cancer*, *Journal of Biological Chemistry*, *Journal of Pharmacology and Experimental Therapeutics*, *Environmental Toxicology*, *Journal of Microencapsulation*, *Anti-Cancer drugs*, *Journal of Food Biochemistry*, *International Journal of Oncology* etc.

I. Συμμετοχή σε οργανωτικές/επιστημονικές επιτροπές συνεδρίων

1. 3rd Congress of the Serbian Association of Cancer Research with international participation. October 2017, Belgrade, Serbia
2. 6th Multidisciplinary Cancer Research Congress. October 2016, Konya, Turkey.
3. 2nd Congress of the Serbian Association of Cancer Research with international participation. October 2015, Belgrade, Serbia.
4. EACR sponsored -3rd Anticancer Agent Development Congress, May 18-19, Izmir, Turkey.
5. Dendrimers as Composites of Advanced Drug Delivery nano Systems (aDDnSs). Biomedical Applications 4 days Training School, October 3-8, 2011, Athens, COST action TD0802.
6. EACR sponsored - Anticancer Agents Research Congress, October 13-16, 2011, Antalya, Turkey

K. Διαλέξεις κατόπιν πρόσκλησης

1. Sigma Ligands as Potential Novel Targeted Anticancer Therapies. 5th International Multithematic Biomedical Scientific Congress-Nicosia Cyprus (IMBMC 2017)
2. Mouse models of Cancer: from basic cancer biology studies to precision medicine. 3rd Congress of the Serbian Association of Cancer Research with international participation. October 2017, Belgrade, Serbia
3. Chemosensitivity-Chemoresistance: development, study, and efficacy testing procedure of anticancer drugs. Dept of Pharmacology, School of Medicine, University of Ioannina, Ioannina, Greece.
4. Sigma ligands as targeted anticancer therapeutics. 6th Multidisciplinary Cancer Research Congress. October 2016, Konya, Turkey
5. Chemosensitivity-Chemoresistance: development, study, and efficacy testing procedure of anticancer drugs. Hellenic Society for Nanotechnology in Health Sciences (HSnanoHS), Democritus Institute, Athens, Greece.
6. Sigma receptors as targets for the development of novel targeted anticancer therapies. 2nd Congress of the Serbian Association of Cancer Research with international participation. October 2015, Belgrade, Serbia
7. Targeting s6 kinases for the development of novel anticancer therapies. EACR sponsored -3rd Anticancer Agent Development Congress, May 18-19, Izmir, Turkey.
8. Anticancer targeted therapies. 10th Conference of the Society of Clinical Oncology of Western Greece. 2015 Patras, Greece.
9. Targeted therapies in Cancer. 8th Conference of the Society for the Study of Metastatic Liver Disease. 2015 Volos Greece.
10. Anticancer drugs-Targeted therapies. Seminars in Cancer Biology. June 2014, BRFAA, Athens, Greece (sponsored by JANSSEN-CILAG).
11. Anticancer efficacy testing using the NCI approach: EACR-sponsored “2nd Anticancer Agents Congress: Targeting Cancer Stem Cell”. 21-24th November 2013, Antalya, Turkey.
12. Chemosensitivity-Chemoresistance: Anticancer drugs’ development, study, and efficacy testing procedure. 2013, Dept of Chemistry, NKUOA, Athens, Greece.
13. Kaempferol Glycosides: Emerging Stars in the Flavonoid Galaxy? IV International Congress of Molecular Medicine, 27-30 June 2012, Istanbul, Turkey.
14. In vitro anticancer screening assays: theory and applications on drug delivery systems. Dendrimers as Composites of Advanced Drug Delivery nano Systems (aDDnSs). Biomedical Applications 4 days Training School, October 3-8, 2011, Athens, COST action TD0802.
15. Labdanes as potential novel chemotherapeutics for cancer. EACR - Anticancer Agents Research Congress, October 13-16, 2011, Antalya, Turkey.
16. Φαρμακολογία Αντικαρκινικών Φαρμάκων, 2011, Κλινική Ογκολογίας, ΠΓΝΑ, Λάρισα.

17. p90 ribosomal S6 kinases: Potential new targets for promising anticancer therapies? Eighth international conference of anticancer research, October 17-22, 2008 Kos, Greece.

A. Μέλος σε επιστημονικές εταιρίες

1. Greek Society for Pharmacology (GSP)
2. Hellenic Society for Molecular Cancer Research (HAMCR)
3. European Association for Cancer Research (EACR) (Ambassador for Greece,)
4. Institute of Molecular Medicine & Biomedical Research, Greece (Assisting Member)
5. Hellenic Society for Nanotechnology in Health Sciences (Founding member)

M. Χρηματοδοτήσεις/Προγράμματα

- Δράση ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ 2017, Κωδικός Τ1ΕΔΚ-01833 (DEMO ΑΕΒΕ, Συνολικός ΠΥ 610894€) *Συνεργαζόμενος Ερευνητής* **154291,54€**
- Δράση ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ 2017, Κωδικός Τ1ΕΔΚ-01612 (Τμήμα Χημείας ΕΚΠΑ, Συνολικός ΠΥ 681760€) *Συνεργαζόμενος Ερευνητής* **150000€**
- Έλεγχος τοξικότητας ενέσιμων σκευασμάτων DEMO ΑΕΒΕ (Ρόλος: ΕΥ) **6900€ (2017)/1500€ (2014)**
- Διερεύνηση της στόχευσης της λειτουργίας του mTOR για την ανάπτυξη νέων προσεγγίσεων αντιμετώπισης των επιθετικών μορφών καρκίνου του θυρεοειδούς (Ρόλος: ΕΥ) **7000€**
- Μελέτη αντικαρκινικής δράσης μικρών χημικών μορίων σε ζωικά προ-κλινικά μοντέλα καρκίνου (Ρόλος: ΕΥ) **1500€**
- Δωρεά εξοπλισμού από το ίδρυμα «Μποδοσάκης» (1 upright -80°C deep freezer)
- Δωρεά εξοπλισμού από το Νοσ. Ο «Άγιος Σάββας» (1 FACSCalibur, 2 Laminar flow hoods, 2 CO₂ Incubators, 1 Zeiss upright microscope)
- COST Action-CM 1407 “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery”
- COST-CM1106 “Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells”
- Αριστεία 2011-PANNANOMED (Ρόλος: *Επιστημονικός Υπεύθυνος για τα πακέτα εργασίας 6 και 7- Κύριος Ερευνητής: Ερμής Ιατρού, Αναπληρωτής Καθηγητής, Τμήμα Χημείας, ΕΚΠΑ*) **150000€**
- Επιχορήγηση από την εταιρεία Medexis SA (Ρόλος: *Κύριος Ερευνητής*) (Study of the anticancer activity of small molecules against animal cancer models) **5000€**
- -COST-TD0802 “Dendrimers in Biomedical applications” (Ρόλος: *Συμμετέχων-Αναπληρωματικός Εθνικός Εκπρόσωπος στην Επιτροπή Διαχείρισης*)
- -Επιχορήγηση από την εταιρία Anavex SA «Novel σ -receptor ligands with potent antitumor activities» **35000€ plus a post doc compensated directly by the company** (Ρόλος: *Κύριος Ερευνητής*)-

- Επιχορήγηση από την εταιρία Γερολυμάτος ΠΝ για το πρόγραμμα “Gerolab” (Pharmaceutical formulations comprising labdane for the treatment of tumors or leukemias). Ρόλος: *Συνεργαζόμενος Ερευνητής* - Κύριος Ερευνητής: Κωνσταντίνος Δεμέτζος, Καθηγητής, Τμήμα Φαρμακευτικής, ΕΚΠΑ)- **(2001-2003:100.000.000δρχ, 2002-2005:90.000.000δρχ, 2004-2005:40,000€, 2006-2007:64000€)**